Visceral leishmaniasis with pleural effusion in an immunocompetent patient

Dasgupta, Senjuti; Saha, M; Chakrabarti, Sudipta; Chakraborty, Jayati

doi:10.4103/0970-2113.125913

Cited by 13 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that COPD is related to lysosome,45 Staphylococcus aureus infection,46 osteoclast differentiation,47 leishmaniasis,48 dilated cardiomyopathy,49 rap1 signaling pathway,50 and PPAR signaling pathway,51 which are concordant with our KEGG pathway results in patients with COPD. In addition, we found 1,115 up-regulated and 346 down-regulated GO terms in biological process, 127 up-regulated and 34 down-regulated GO terms in cellular component, and 115 up-regulated and 53 down-regulated GO terms in molecular function between COPD lung tissues and non-COPD lung tissues according to the GO analysis results.…”

Section: Discussionsupporting

confidence: 91%

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD

Tang¹,

Shen²,

Guo³

et al. 2016

COPD

View full text Add to dashboard Cite

ObjectiveTo evaluate differentially expressed long noncoding RNAs (lncRNAs) and the potential role of lncRNA TUG1 in patients with chronic obstructive pulmonary disease (COPD).MethodsTotal RNA was extracted from both COPD and non-COPD lung tissues, and microarray analysis was performed with 25,628 lncRNA probes and 20,106 mRNA probes. In addition, five up-regulated and five down-regulated lncRNAs were selected for identification using quantitative real-time polymerase chain reaction. COPD cell model was established by transforming growth factor β (TGF-β) treatment. Cell Counting Kit-8 assay was used to detect BEAS-2B and HFL1 cell proliferation after TUG-siRNA transfection with TGF-β treatment. In addition, the expression levels of α-SMA and fibronectin proteins were determined using Western blot in BEAS-2B and HFL1 cells after TUG-siRNA transfection with TGF-β treatment.ResultsThere were 8,376 (32.7%) differentially expressed lncRNAs and 5,094 (25.3%) differentially expressed mRNAs in COPD lung tissues compared with non-COPD lung tissues. Five of the analyzed lncRNAs (BC038205, BC130595, TUG1, MEG3, and LOC646329) were markedly increased, while five lncRNAs (LOC729178, PLAC2, LOC339529, LINC00229, and SNHG5) were significantly decreased in COPD lung tissues compared with non-COPD lung tissues (n=20) (***P<0.001). Knockdown of lncRNA TUG1 promotes BEAS-2B and HFL1 cell proliferation after TGF-β treatment through inhibiting the expression levels of α-SMA and fibronectin.ConclusionAbundant, differentially expressed lncRNAs and mRNAs were identified by microarray analysis and these might play a partial or key role in the diagnosis of patients with COPD. LncRNA TUG1 may become a very important class of biomarker and may act as a potential diagnostic and therapeutic target for patients with COPD.

show abstract

Section: Discussionsupporting

confidence: 91%

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD

Tang¹,

Shen²,

Guo³

et al. 2016

COPD

View full text Add to dashboard Cite

show abstract

“…VL is a disease characterized by systemic involvement and a broad spectrum of clinical manifestations. Pulmonary involvement in this parasitosis is even considered uncommon in immunocompetent patients [17]. However, the frequency of respiratory symptoms and tomographic changes found in the present study demonstrate that the involvement of the respiratory system in VL is more common than previously thought and deserves attention.…”

Section: Discussionmentioning

confidence: 42%

“…Chest X-ray revealed pneumonia in only two patients in the study, and both reported respiratory symptoms. Nodular tomographic pattern and increased pulmonary opacity found in our sample are considered suggestive of interstitial disease, but may also be due to bacterial infection [17,31]. Thus, the frequency of secondary bacterial pneumonia may be higher than that found on plain radiographs.…”

Section: Normal-n (%) Changed-n (%) P-valuementioning

confidence: 53%

See 1 more Smart Citation

Pulmonary involvement in human visceral leishmaniasis: Clinical and tomographic evaluation

Bispo

Almeida

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is a severe, systemic and potentially lethal parasitosis. The lung, like any other organ, can be affected in VL, and interstitial pneumonitis has been described in past decades. This research aimed to bring more recent knowledge about respiratory impairment in VL, characterizing pulmonary involvement through clinical, radiographic and tomographic evaluation. This is an observational, cross-sectional study that underwent clinical evaluation, radiography and high-resolution computed tomography of the chest in patients admitted with the diagnosis of VL in a university service in Northeast Brazil, from January 2015 to July 2018. The sample consisted of 42 patients. Computed tomography was considered abnormal in 59% of patients. Images compatible with pulmonary interstitial involvement were predominant (50%). The most observed respiratory symptom was cough (33.3%), followed by tachypnea (14.1%). Chest radiography was altered in only four patients. VL is a disease characterized by systemic involvement and broad spectrum of clinical manifestations. The respiratory symptoms and tomographic alterations found show that the involvement of respiratory system in VL deserves attention because it is more common than previously thought. Chest X-ray may not reveal this impairment.

show abstract

“…In bone marrow and peripheral blood smear, Leishmania amastigotes were observed. Intravenous sodium stibogluconate started and pleural effusion resolved after one month (13).…”

Section: Discussionmentioning

confidence: 99%

Visceral Leishmaniasis with Massive Pulmonary Involvement: A Case Report

et al. 2019

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is an endemic disease in East and South Africa and the Mediterranean area. Fever, splenomegaly, and weakness are the most common symptoms of VL, but pulmonary involvement is very rare. The present study reports a patient with VL and pulmonary complication. An 18-year-old immunocompetent patient was referred to a local hospital with submandibular lymphadenopathy, nonproductive cough, and occasional fever. In spiral chest CT scan, bilateral massive bronchopulmonary consolidation with a diffused nodular pattern was seen. After a few days, because of absent response to antibiotic therapy and prednisolone, fine needle aspiration from pulmonary nodules was done that showed multiplex Leishman bodies. The patient showed a good response to amphotericin B and glucantime.

show abstract

Visceral leishmaniasis with pleural effusion in an immunocompetent patient

Cited by 13 publications

References 9 publications

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD

Pulmonary involvement in human visceral leishmaniasis: Clinical and tomographic evaluation

Visceral Leishmaniasis with Massive Pulmonary Involvement: A Case Report

Contact Info

Product

Resources

About

Visceral leishmaniasis with pleural effusion in an immunocompetent patient

Cited by 13 publications

References 9 publications

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-&beta; induction in patients with COPD

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-&beta; induction in patients with COPD

Pulmonary involvement in human visceral leishmaniasis: Clinical and tomographic evaluation

Visceral Leishmaniasis with Massive Pulmonary Involvement: A Case Report

Contact Info

Product

Resources

About

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD

Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD